Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types

An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minghui Li, Jing Yuan, Gang Lv, Jacob Brown, Xiangxiang Jiang, Zhiqiang Kevin Lu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 vaccine mRNA vaccine myocarditis pericarditis age Medicine R
Acceso en línea:	https://doaj.org/article/5ea464cbc4964c94a6f2711a7dcfcdec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ea464cbc4964c94a6f2711a7dcfcdec
record_format	dspace
spelling	oai:doaj.org-article:5ea464cbc4964c94a6f2711a7dcfcdec2021-11-25T18:07:15ZMyocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types10.3390/jpm111111062075-4426https://doaj.org/article/5ea464cbc4964c94a6f2711a7dcfcdec2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1106https://doaj.org/toc/2075-4426An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73–6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21–3.83; BNT162b2 (Pfizer–BioNTech): ROR = 5.37, 95% CI = 4.10–7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99–1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration.Minghui LiJing YuanGang LvJacob BrownXiangxiang JiangZhiqiang Kevin LuMDPI AGarticleCOVID-19 vaccinemRNA vaccinemyocarditispericarditisageMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1106, p 1106 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 vaccine mRNA vaccine myocarditis pericarditis age Medicine R
spellingShingle	COVID-19 vaccine mRNA vaccine myocarditis pericarditis age Medicine R Minghui Li Jing Yuan Gang Lv Jacob Brown Xiangxiang Jiang Zhiqiang Kevin Lu Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
description	An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73–6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21–3.83; BNT162b2 (Pfizer–BioNTech): ROR = 5.37, 95% CI = 4.10–7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99–1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration.
format	article
author	Minghui Li Jing Yuan Gang Lv Jacob Brown Xiangxiang Jiang Zhiqiang Kevin Lu
author_facet	Minghui Li Jing Yuan Gang Lv Jacob Brown Xiangxiang Jiang Zhiqiang Kevin Lu
author_sort	Minghui Li
title	Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_short	Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_full	Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_fullStr	Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_full_unstemmed	Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_sort	myocarditis and pericarditis following covid-19 vaccination: inequalities in age and vaccine types
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5ea464cbc4964c94a6f2711a7dcfcdec
work_keys_str_mv	AT minghuili myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT jingyuan myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT ganglv myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT jacobbrown myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT xiangxiangjiang myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT zhiqiangkevinlu myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes
_version_	1718411618361016320

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types

Ejemplares similares